Rejecting an appeal, the Federal Competition Commission voted 4 to 1 to fine the companies $11.6 million for conspiring to raise prices of meds sold to a social-services agency, Instituto Mexicano del Seguro Social, according to this statement. The decision comes shortly after the antitrust regulator indictated new investigations may be launched into drugmakers for scheming to inflate prices (background).
read the rest at www.pharmalot.com
IMSS healthcare suffers only because it exists in a poor country. It is an excellent model that the US could do worse than imitate.